Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Artemether-lumefantrine plus primaquine surveillance for uncomplicated falciparum and vivax malaria in Lao PDR
ACTRN12623000241639Phase 4Recruiting
- Sponsor
- Ministry of Health
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of lumefantrine and primaquine in Malaria and malaria (2 arms), sponsored by Ministry of Health. Primary endpoint: Composite efficacy outcome. Started Oct 2022; status: recruiting.
02
Drugs
lumefantrineprimaquine
03
Conditions
Malariamalaria
Beyond the preview
Go deeper on ACTRN12623000241639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623000241639.